NRXPNRX Pharmaceuticals, Inc.

Nasdaq nrxpharma.com


$ 4.00 $ 0.03 (0.76 %)    

Monday, 03-Jun-2024 11:10:17 EDT
QQQ $ 454.82 $ -1.87 (-0.41 %)
DIA $ 398.57 $ -2.47 (-0.64 %)
SPY $ 530.36 $ -2.59 (-0.49 %)
TLT $ 91.26 $ 0.78 (0.86 %)
GLD $ 225.37 $ 0.99 (0.46 %)
$ 3.81
$ 3.97
$ 0.00 x 0
$ 0.00 x 0
$ 3.97 - $ 4.00
$ 1.90 - $ 54.00
64,953
na
33.73M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-21-2021 03-31-2021 10-Q
13 04-01-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-15-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-15-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-23-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nrx-pharmaceuticals-presents-landmark-trial-of-nrx-101-in-suicidal-bipolar-depression-at-the-ascp-annual-meeting-nrx-101-is-the-first-oral-antidepressant-demonstrated-to-reduce-suicidality-in-bipolar-depression

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidon...

 nrx-pharmaceuticals-q1-eps-074-misses-037-estimate

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of...

 why-is-nrx-pharmaceuticals-stock-falling-after-data-from-suicidal-bipolar-depression-study

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.

 dow-surges-over-100-points-dr-horton-posts-upbeat-earnings

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market...

 nrx-pharmaceuticals-receives-notice-from-nasdaq-that-the-company-has-demonstrated-compliance-with-the-bid-price-requirement

The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closi...

 nrx-pharmaceuticals-inc-announces-pricing-of-2m-underwritten-public-offering-of-common-stock-at-a-public-offering-price-of-330-per-share

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmace...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION